Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals - NEC
- Sub-Industry: Health Care Equipment
- Symbol: NYSE:ABT
- CUSIP: 00282410
- Web: www.abbott.com
Capitalization:- Market Cap: $84.68298 billion
- Outstanding Shares: 1,737,443,000
Average Prices:- 50 Day Moving Avg: $49.15
- 200 Day Moving Avg: $45.95
- 52 Week Range: $37.38 - $51.13
P/E:- Trailing P/E Ratio: 68.26
- Foreward P/E Ratio: 17.47
- P/E Growth: 1.76
Sales & Book Value:- Annual Revenue: $23.61 billion
- Price / Sales: 3.59
- Book Value: $18.19 per share
- Price / Book: 2.68
Dividend:- Annual Dividend: $1.06
- Dividend Yield: 2.2%
Profitability:- EBIDTA: $5.14 billion
- Net Margins: 4.96%
- Return on Equity: 14.43%
- Return on Assets: 6.47%
Debt:- Debt-to-Equity Ratio: 0.75%
- Current Ratio: 2.94%
- Quick Ratio: 2.41%
Misc:- Average Volume: 6.06 million shs.
- Beta: 1.07
- Short Ratio: 2.35
Frequently Asked Questions for Abbott Laboratories (NYSE:ABT)
What is Abbott Laboratories' stock symbol?
Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."
How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?
Abbott Laboratories declared a quarterly dividend on Friday, June 9th. Stockholders of record on Friday, July 14th will be given a dividend of $0.265 per share on Tuesday, August 15th. This represents a $1.06 dividend on an annualized basis and a dividend yield of 2.17%. The ex-dividend date of this dividend is Wednesday, July 12th. View Abbott Laboratories' Dividend History.
How were Abbott Laboratories' earnings last quarter?
Abbott Laboratories (NYSE:ABT) released its earnings results on Thursday, July, 20th. The company reported $0.62 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.60 by $0.02. The business had revenue of $6.64 billion for the quarter, compared to analyst estimates of $6.63 billion. Abbott Laboratories had a net margin of 4.96% and a return on equity of 14.43%. The company's quarterly revenue was up 24.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.55 earnings per share. View Abbott Laboratories' Earnings History.
When will Abbott Laboratories make its next earnings announcement?
What guidance has Abbott Laboratories issued on next quarter's earnings?
Abbott Laboratories issued an update on its third quarter earnings guidance on Thursday, July, 20th. The company provided earnings per share guidance of $0.64-0.66 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.66. Abbott Laboratories also updated its FY17 guidance to $2.43-2.53 EPS.
Where is Abbott Laboratories' stock going? Where will Abbott Laboratories' stock price be in 2017?
13 brokerages have issued 12-month target prices for Abbott Laboratories' stock. Their predictions range from $42.00 to $58.00. On average, they expect Abbott Laboratories' stock price to reach $52.83 in the next twelve months. View Analyst Ratings for Abbott Laboratories.
Who are some of Abbott Laboratories' key competitors?
Some companies that are related to Abbott Laboratories include Merck & Company (MRK), Sanofi (SNY), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Bristol-Myers Squibb Company (BMY), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Patheon NV (PTHN), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Taro Pharmaceutical Industries (TARO), Akorn (AKRX) and Opko Health (OPK).
Who are Abbott Laboratories' key executives?
Abbott Laboratories' management team includes the folowing people:
- Miles D. White, Chairman of the Board, Chief Executive Officer
- Brian B. Yoor, Chief Financial Officer, Senior Vice President - Finance
- Michael T. Rousseau, President - Cardiovascular and Neuromodulation
- Hubert L. Allen, Executive Vice President, General Counsel, Secretary
- Stephen R. Fussell, Executive Vice President - Human Resources
- Brian J. Blaser, Executive Vice President - Diagnostics Products
- John M. Capek Ph.D., Executive Vice President - Ventures
- Robert B. Ford, Executive Vice President - Medical Devices
- Heather L. Mason, Executive Vice President - Nutritional Products
- Roger Bird, Senior Vice President - U.S. Nutrition
Who owns Abbott Laboratories stock?
Abbott Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.48%), BlackRock Inc. (6.01%), State Street Corp (4.43%), Capital Research Global Investors (2.74%), Bank of New York Mellon Corp (1.94%) and Northern Trust Corp (1.55%). Company insiders that own Abbott Laboratories stock include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.
Who sold Abbott Laboratories stock? Who is selling Abbott Laboratories stock?
Abbott Laboratories' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Renaissance Technologies LLC, Fort Washington Investment Advisors Inc. OH, FMR LLC, Macquarie Group Ltd., BlackRock Inc., Prudential PLC and DnB Asset Management AS. Company insiders that have sold Abbott Laboratories stock in the last year include Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jared Watkin, Joseph J Manning, Michael J Warmuth, Robert E Funck, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.
Who bought Abbott Laboratories stock? Who is buying Abbott Laboratories stock?
Abbott Laboratories' stock was acquired by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Janus Henderson Group PLC, Vanguard Group Inc., Dimensional Fund Advisors LP, Boston Partners, Principal Financial Group Inc., Parametric Portfolio Associates LLC and Hexavest Inc.. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.
How do I buy Abbott Laboratories stock?
Shares of Abbott Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abbott Laboratories' stock price today?
One share of Abbott Laboratories stock can currently be purchased for approximately $48.74.
MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Abbott Laboratories (NYSE:ABT) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Hold Ratings, 9 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.69) |
| Consensus Price Target: | $52.83 (8.40% upside) |
Analysts' Ratings History for Abbott Laboratories (NYSE:ABT)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/17/2017 | Citigroup Inc. | Initiated Coverage | Neutral -> Neutral | $53.00 | Medium |  |
| 8/17/2017 | Cowen and Company | Reiterated Rating | Buy | $55.00 | Medium | |
| 8/3/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $58.00 | Low | |
| 7/22/2017 | Barclays PLC | Reiterated Rating | Overweight | $52.00 -> $57.00 | Low | |
| 7/21/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $58.00 | Low | |
| 7/11/2017 | BMO Capital Markets | Reiterated Rating | Hold | $48.00 | Low | |
| 7/10/2017 | Morgan Stanley | Reiterated Rating | Equal Weight | | Low | |
| 6/30/2017 | Wells Fargo & Company | Reiterated Rating | Outperform | $47.50 -> $54.00 | Low | |
| 6/29/2017 | Guggenheim | Initiated Coverage | Buy | $58.00 | Low | |
| 6/21/2017 | BTIG Research | Initiated Coverage | Buy | $56.00 | Low | |
| 5/16/2017 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Neutral -> Neutral | $45.00 | Low | |
| 5/15/2017 | Royal Bank Of Canada | Reiterated Rating | Buy | | Low | |
| 9/19/2016 | Bank of America Corporation | Reiterated Rating | Buy | | N/A | |
| 8/9/2016 | Deutsche Bank AG | Reiterated Rating | Buy | | N/A | |
| 7/28/2016 | Argus | Reiterated Rating | Buy | $55.00 | N/A | |
| 6/21/2016 | Edward Jones | Upgrade | Hold -> Buy | | N/A | |
| 6/8/2016 | Credit Suisse Group | Reiterated Rating | Buy | | N/A | |
| 4/30/2016 | S&P Equity Research | Reiterated Rating | Hold | | N/A | |
| 4/30/2016 | Gabelli | Reiterated Rating | Buy | | N/A | |
| 4/28/2016 | Piper Jaffray Companies | Downgrade | Overweight -> Neutral | | N/A | |
| 4/14/2016 | First Global | Downgrade | Outperform -> Marketperform | | N/A | |
| 3/28/2016 | Leerink Swann | Boost Price Target | Market Perform | $37.00 -> $40.00 | N/A | |
| 1/29/2016 | Raymond James Financial, Inc. | Lower Price Target | Outperform | $46.00 -> $42.00 | N/A | |
| 1/29/2016 | William Blair | Downgrade | Outperform -> Market Perform | | N/A | |
(Data available from 8/20/2015 forward)
Earnings History for Abbott Laboratories (NYSE:ABT)Earnings History by Quarter for Abbott Laboratories (NYSE ABT)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/17/2017 | | $0.66 | | | | | N/A | |
| 7/20/2017 | Q2 2017 | $0.60 | $0.62 | $6.63 billion | $6.64 billion | View | N/A | |
| 4/19/2017 | 3/31/2017 | $0.43 | $0.48 | $6.16 billion | $6.34 billion | View | N/A | |
| 1/25/2017 | Q416 | $0.64 | $0.65 | $5.41 billion | $5.33 billion | View | Listen | |
| 10/19/2016 | Q316 | $0.58 | $0.59 | $5.29 billion | $5.30 billion | View | Listen | |
| 7/20/2016 | Q216 | $0.53 | $0.55 | $5.24 billion | $5.30 billion | View | Listen | |
| 4/20/2016 | Q116 | $0.39 | $0.41 | $4.77 billion | $4.90 billion | View | Listen | |
| 1/28/2016 | Q415 | $0.61 | $0.62 | $5.31 billion | $5.20 billion | View | Listen | |
| 10/21/2015 | Q315 | $0.53 | $0.54 | $5.16 billion | $5.15 billion | View | Listen | |
| 7/22/2015 | Q215 | $0.50 | $0.52 | $5.15 billion | $5.20 billion | View | Listen | |
| 4/22/2015 | Q115 | $0.42 | $0.47 | $4.85 billion | $4.90 billion | View | Listen | |
| 1/29/2015 | Q414 | $0.68 | $0.71 | $5.48 billion | $5.36 billion | View | Listen | |
| 10/22/2014 | Q314 | $0.60 | $0.62 | $5.62 billion | $5.10 billion | View | Listen | |
| 7/16/2014 | Q214 | $0.51 | $0.54 | $5.53 billion | $5.55 billion | View | Listen | |
| 4/16/2014 | Q114 | $0.36 | $0.41 | $5.29 billion | $5.24 billion | View | Listen | |
| 1/22/2014 | Q413 | $0.58 | $0.58 | $5.72 billion | $5.66 billion | View | Listen | |
| 10/16/2013 | Q313 | $0.52 | $0.55 | $5.46 billion | $5.37 billion | View | Listen | |
| 7/17/2013 | Q2 2013 | $0.44 | $0.46 | $5.53 billion | $5.45 billion | View | Listen | |
| 4/17/2013 | Q1 2013 | $0.41 | $0.42 | $5.42 billion | $5.38 billion | View | Listen | |
| 1/23/2013 | Q4 2012 | $1.50 | $1.51 | $10.58 billion | $10.80 billion | View | Listen | |
| 10/17/2012 | | $1.28 | $1.30 | | | View | N/A | |
| 7/18/2012 | | $1.22 | $1.23 | | | View | N/A | |
| 4/18/2012 | | $1.00 | $1.03 | | | View | N/A | |
| 1/25/2012 | | $1.44 | $1.45 | | | View | N/A | |
| 10/19/2011 | | $1.17 | $1.18 | | | View | N/A | |
| 7/20/2011 | | $1.12 | $1.12 | | | View | N/A | |
| 4/20/2011 | | $0.90 | $0.91 | | | View | N/A | |
| 1/26/2011 | | $1.29 | $1.30 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Abbott Laboratories (NYSE:ABT)2017 EPS Consensus Estimate: $2.44
2018 EPS Consensus Estimate: $2.83
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $0.43 | $0.50 | $0.45 |
| Q2 2017 | 3 | $0.59 | $0.61 | $0.60 |
| Q3 2017 | 3 | $0.64 | $0.68 | $0.66 |
| Q4 2017 | 3 | $0.72 | $0.73 | $0.73 |
| Q1 2018 | 2 | $0.55 | $0.56 | $0.56 |
| Q2 2018 | 2 | $0.69 | $0.71 | $0.70 |
| Q3 2018 | 2 | $0.74 | $0.76 | $0.75 |
| Q4 2018 | 2 | $0.80 | $0.84 | $0.82 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Abbott Laboratories (NYSE:ABT)| Most Recent Dividend: | 8/15/2017 |
| Annual Dividend: | $1.06 |
| Dividend Yield: | 2.17% |
| Dividend Growth: | 22.90% (3 Year Average) |
| Payout Ratio: | 149.30% (Trailing 12 Months of Earnings)
42.74% (Based on This Year's Estimates)
37.99% (Based on Next Year's Estimates)
|
| Track Record: | 44 Years of Consecutive Dividend Growth |
Dividend History by Quarter for Abbott Laboratories (NYSE ABT)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 6/9/2017 | quarterly | $0.27 | 2.25% | 7/12/2017 | 7/14/2017 | 8/15/2017 |
| 2/17/2017 | quarterly | $0.27 | 2.36% | 4/11/2017 | 4/14/2017 | 5/15/2017 |
| 12/9/2016 | quarterly | $0.27 | 2.7% | 1/11/2017 | 1/13/2017 | 2/15/2017 |
| 9/15/2016 | quarterly | $0.26 | 2.48% | 10/12/2016 | 10/14/2016 | 11/15/2016 |
| 6/10/2016 | quarterly | $0.26 | 2.75% | 7/13/2016 | 7/15/2016 | 8/15/2016 |
| 2/19/2016 | quarterly | $0.26 | 2.66% | 4/13/2016 | 4/15/2016 | 5/16/2016 |
| 12/11/2015 | quarterly | $0.26 | 2.32% | 1/13/2016 | 1/15/2016 | 2/16/2016 |
| 9/17/2015 | quarterly | $0.24 | 2.22% | 10/13/2015 | 10/15/2015 | 11/15/2015 |
| 6/12/2015 | quarterly | $0.24 | 2% | 7/13/2015 | 7/15/2015 | 8/15/2015 |
| 2/20/2015 | quarterly | $0.24 | 2.03% | 4/13/2015 | 4/15/2015 | 5/15/2015 |
| 12/12/2014 | quarterly | $0.24 | 2.21% | 1/13/2015 | 1/15/2015 | 2/13/2015 |
| 9/11/2014 | quarterly | $0.22 | 2.07% | 10/10/2014 | 10/15/2014 | 11/15/2014 |
| 6/13/2014 | quarterly | $0.22 | 2.21% | 7/11/2014 | 7/15/2014 | 8/15/2014 |
| 2/21/2014 | quarterly | $0.22 | 2.26% | 4/11/2014 | 4/15/2014 | 5/15/2014 |
| 10/16/2013 | quarterly | $0.22 | 2.37% | 1/13/2014 | 1/15/2014 | 2/15/2014 |
| 9/12/2013 | quarterly | $0.14 | 1.61% | 10/10/2013 | 10/15/2013 | 11/15/2013 |
| 6/14/2013 | quarterly | $0.14 | 1.52% | 7/11/2013 | 7/15/2013 | 8/15/2013 |
| 2/15/2013 | quarterly | $0.14 | 1.61% | 4/11/2013 | 4/15/2013 | 5/15/2013 |
| 12/14/2012 | quarterly | $0.14 | 0.86% | 1/11/2013 | 1/15/2013 | 2/15/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Abbott Laboratories (NYSE:ABT)Insider Ownership Percentage: 0.76%
Institutional Ownership Percentage: 70.86%
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/16/2017 | Stephen R Fussell | Insider | Sell | 196,550 | $49.50 | $9,729,225.00 | |
| 8/1/2017 | Sharon J Bracken | Insider | Sell | 2,000 | $49.16 | $98,320.00 | |
| 7/27/2017 | Brian J Blaser | Insider | Sell | 15,000 | $50.00 | $750,000.00 | |
| 7/25/2017 | Hubert L Allen | Insider | Sell | 4,600 | $50.79 | $233,634.00 | |
| 6/15/2017 | Jared Watkin | Insider | Sell | 552 | $47.97 | $26,479.44 | |
| 6/8/2017 | Stephen R Fussell | Insider | Sell | 196,550 | $46.00 | $9,041,300.00 | |
| 4/27/2017 | Roger Bird | Insider | Sell | 5,600 | $43.82 | $245,392.00 | |
| 4/26/2017 | Joseph J Manning | Insider | Sell | 4,200 | $43.95 | $184,590.00 | |
| 3/1/2017 | Michael J. Warmuth | Insider | Sell | 3,851 | $45.39 | $174,796.89 | |
| 2/23/2017 | Robert E Funck | VP | Sell | 25,500 | $45.50 | $1,160,250.00 | |
| 2/22/2017 | Roger Bird | Insider | Sell | 13,222 | $45.02 | $595,254.44 | |
| 2/21/2017 | Deepak S Nath | Insider | Sell | 319 | $44.98 | $14,348.62 | |
| 1/31/2017 | Heather L Mason | Insider | Sell | 35,700 | $40.77 | $1,455,489.00 | |
| 12/20/2016 | Brian J Blaser | Insider | Buy | 15,580 | $38.45 | $599,051.00 | |
| 12/14/2016 | Robert B Ford | Insider | Buy | 12,775 | $39.09 | $499,374.75 | |
| 11/10/2016 | Miles D White | Chairman | Buy | 121,456 | $40.45 | $4,912,895.20 | |
| 11/1/2016 | Sally E Blount | Director | Buy | 5,100 | $39.24 | $200,124.00 | |
| 9/26/2016 | Daniel Gesua Sive Salvadori | SVP | Sell | 815 | $41.71 | $33,993.65 | |
| 7/28/2016 | Stephen R Fussell | Insider | Sell | 41,500 | $45.00 | $1,867,500.00 | |
| 7/26/2016 | Michael J Warmuth | Insider | Sell | 26,800 | $43.49 | $1,165,532.00 | |
| 7/25/2016 | Miles D White | Chairman | Buy | 242,547 | $43.18 | $10,473,179.46 | |
| 7/25/2016 | Robert E Funck | VP | Sell | 26,800 | $43.08 | $1,154,544.00 | |
| 6/28/2016 | Hubert L Allen | EVP | Sell | 3,400 | $37.14 | $126,276.00 | |
| 6/15/2016 | Jared Watkin | SVP | Sell | 552 | $37.63 | $20,771.76 | |
| 6/1/2016 | Brian B Yoor | CFO | Sell | 565 | $39.49 | $22,311.85 | |
| 4/28/2016 | Deepak S Nath | SVP | Sell | 53 | $41.31 | $2,189.43 | |
| 3/31/2016 | Jaime Contreras | SVP | Sell | 462 | $41.78 | $19,302.36 | |
| 2/29/2016 | Brian B Yoor | CFO | Sell | 865 | $39.12 | $33,838.80 | |
| 2/29/2016 | Deepak S Nath | SVP | Sell | 793 | $39.27 | $31,141.11 | |
| 2/29/2016 | Robert B Ford | EVP | Sell | 1,706 | $39.28 | $67,011.68 | |
| 2/29/2016 | Robert E Funck | VP | Sell | 1,333 | $39.30 | $52,386.90 | |
| 2/22/2016 | Jared Watkin | SVP | Sell | 554 | $39.09 | $21,655.86 | |
| 2/16/2016 | Deepak S. Nath | SVP | Sell | 171 | $37.13 | $6,349.23 | |
| 12/16/2015 | Miles D. White | CEO | Sell | 438,000 | $46.00 | $20,148,000.00 | |
| 8/18/2015 | Stephen R. Fussell | EVP | Sell | 13,096 | $50.46 | $660,824.16 | |
| 4/27/2015 | Heather L Mason | EVP | Sell | 13,500 | $47.45 | $640,575.00 | |
| 4/27/2015 | Roger Bird | SVP | Sell | 28,548 | $47.57 | $1,358,028.36 | |
| 3/26/2015 | J. Scott White | SVP | Sell | 12,483 | $46.68 | $582,706.44 | |
| 3/2/2015 | Jaime Contreras | SVP | Sell | 9,209 | $47.34 | $435,954.06 | |
| 2/4/2015 | John M Capek | EVP | Sell | 34,292 | $45.66 | $1,565,772.72 | |
| 11/25/2014 | Jaime Contreras | SVP | Sell | 51,600 | $44.07 | $2,274,012.00 | |
| 10/29/2014 | Miles D White | CEO | Sell | 440,800 | $42.52 | $18,742,816.00 | |
| 3/3/2014 | John Landgraf | EVP | Sell | 17,293 | $39.38 | $680,998.34 | |
| 3/3/2014 | Katherine Doyle | SVP | Sell | 6,639 | $39.01 | $258,987.39 | |
| 3/3/2014 | Robert Funck | VP | Sell | 1,413 | $38.97 | $55,064.61 | |
| 2/18/2014 | John Landgraf | EVP | Sell | 1,583 | $39.10 | $61,895.30 | |
| 1/29/2014 | Michael Warmuth | EVP | Sell | 11,430 | $36.21 | $413,880.30 | |
| 12/6/2013 | Jean-Yves Pavee | SVP | Sell | 5,855 | $37.46 | $219,328.30 | |
| 11/7/2013 | Stephen Fussell | EVP | Sell | 10,466 | $37.59 | $393,416.94 | |
| 10/30/2013 | Jaime Contreras | SVP | Sell | 25,368 | $36.85 | $934,810.80 | |
| 6/7/2013 | Heather L Mason | SVP | Sell | 12,000 | $37.01 | $444,120.00 | |
| 2/1/2013 | William A Osborn | Director | Buy | 10,000 | $33.86 | $338,600.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Abbott Laboratories (NYSE:ABT)
Latest Headlines for Abbott Laboratories (NYSE:ABT)
| Source: |
|
| Date | Headline |
|---|
 | Abbott Laboratories (ABT) Insider Sells $9,729,225.00 in Stock
www.americanbankingnews.com - August 18 at 7:26 PM |
 | Citi Starts Abbott Labs (ABT) at Neutral - StreetInsider.com
www.streetinsider.com - August 18 at 1:48 AM |
| Abbott Laboratories (ABT) Now Covered by Citigroup Inc.
www.americanbankingnews.com - August 17 at 11:28 AM |
 | Getting Defensive: Buying Abbott Laboratories And Dominion Energy - Seeking Alpha
seekingalpha.com - August 16 at 3:22 PM |
 | Abbott-North West London Pathology Expand in Diagnostics
finance.yahoo.com - August 16 at 3:21 PM |
| North West London Pathology and Abbott Partner for Diagnostics Products and Services, including Alinity™, in Three NHS Trusts
finance.yahoo.com - August 15 at 3:35 PM |
| [$$] Investment in Heart Disease Treatments Slips in First Half
finance.yahoo.com - August 14 at 3:28 PM |
| Abbott Announces Extension of Cash Tender Offer for All Outstanding Shares of Series B Convertible Perpetual Preferred Stock of Alere Inc.
finance.yahoo.com - August 14 at 3:28 PM |
| Pfizer’s Major Growth Drivers in 2Q17
finance.yahoo.com - August 14 at 3:28 PM |
| Keeley All Cap Value Fund 2nd Quarter Shareholder Commentary
finance.yahoo.com - August 14 at 3:28 PM |
| Edited Transcript of ABT earnings conference call or presentation 20-Jul-17 1:00pm GMT
finance.yahoo.com - August 12 at 3:22 AM |
| Reviewing Abbott Laboratories (NYSE:ABT) & Johnson & Johnson (JNJ)
www.americanbankingnews.com - August 11 at 4:48 PM |
| Abbott Laboratories breached its 50 day moving average in a Bearish Manner : ABT-US : August 11, 2017
finance.yahoo.com - August 11 at 3:38 PM |
 | A nutrition scientist predicts a future in which pizza is nutritious as a superfood
www.businessinsider.com - August 10 at 9:51 PM |
| IHS Markit Score Update: Drop in demand for ETFs holding Abbott Laboratories is a negative sign for its shares
finance.yahoo.com - August 10 at 4:49 PM |
| The Cost of Malnutrition: Study Shows Nutrition Program Could Save Hospitals up to $3,800 per Patient
finance.yahoo.com - August 10 at 4:49 PM |
| See what the IHS Markit Score report has to say about Abbott Laboratories.
finance.yahoo.com - August 10 at 1:39 AM |
| July Portfolio Update: Our Dividend Income Is Going Up, Up, Up!
seekingalpha.com - August 7 at 9:26 PM |
| Siemens to update medical scanner software to deal with security bugs
finance.yahoo.com - August 7 at 4:25 PM |
| Abbott Laboratories (ABT) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - August 6 at 8:56 AM |
| Abbott Laboratories (ABT) Insider Sharon J. Bracken Sells 2,000 Shares
www.americanbankingnews.com - August 3 at 9:04 PM |
| No more freebies? India plans crackdown on marketing by drugmakers
finance.yahoo.com - August 2 at 3:20 PM |
| Abbott Laboratories (ABT) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - August 2 at 2:36 PM |
| Healthcare Stocks: Calm After The Storm?
finance.yahoo.com - August 1 at 3:39 PM |
| AbbVie Drops; Getting Bullish: Part 1 - Focus On Q2 And Humira
seekingalpha.com - July 31 at 3:38 PM |
| FDA clears Alere's Fentanyl urine test - Seeking Alpha
seekingalpha.com - July 31 at 3:38 PM |
| Abbott Laboratories (NYSE:ABT) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 29 at 8:39 AM |
| Brian J. Blaser Sells 15,000 Shares of Abbott Laboratories (ABT) Stock
www.americanbankingnews.com - July 28 at 7:12 PM |
 | Freeport-McMoRan, Apple Hospitality REIT, Abbott Laboratories: 'Mad Money' Lightning Round - TheStreet.com
www.thestreet.com - July 28 at 3:38 PM |
| Abbott Laboratories (NYSE:ABT) Insider Sells $233,634.00 in Stock
www.americanbankingnews.com - July 27 at 7:43 PM |
 | Breakfast Technical Briefing on Medical Equipment Stocks -- Abbott Labs, Boston Scientific, Medtronic, and MiMedx
www.bizjournals.com - July 26 at 8:18 PM |
| Buying Abbott Near Its Peak - Seeking Alpha
seekingalpha.com - July 26 at 3:18 PM |
| Analysts Raise Recommendations on Abbott Stock after 2Q17
finance.yahoo.com - July 26 at 3:18 PM |
| The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger
finance.yahoo.com - July 26 at 3:18 PM |
| Strong 2Q17 Results Trigger Rise in Abbott Stock
finance.yahoo.com - July 25 at 3:20 PM |
| Abbott Laboratories’ 2Q17 Results: Which Segment Fared Best?
finance.yahoo.com - July 25 at 3:19 PM |
| What Were Abbott’s Key Growth Drivers for 2Q17?
finance.yahoo.com - July 25 at 3:19 PM |
| A Review Of The Dividend House Portfolio: Time For A House Inspection
seekingalpha.com - July 24 at 11:56 PM |
| Abiomed Expects to Expand Its Presence in This Space
finance.yahoo.com - July 24 at 1:53 PM |
| FY2018 Earnings Estimate for Abbott Laboratories (ABT) Issued By Gabelli
www.americanbankingnews.com - July 24 at 11:02 AM |
| Abbott Laboratories Expected to Post FY2017 Earnings of $2.50 Per Share (NYSE:ABT)
www.americanbankingnews.com - July 24 at 8:49 AM |
| FY2017 Earnings Estimate for Abbott Laboratories (ABT) Issued By William Blair
www.americanbankingnews.com - July 24 at 8:49 AM |
| Jefferies Group Comments on Abbott Laboratories' Q3 2017 Earnings (ABT)
www.americanbankingnews.com - July 24 at 7:50 AM |
| Abbott Laboratories (NYSE:ABT) Expected to Post Quarterly Sales of $6.66 Billion
www.americanbankingnews.com - July 23 at 12:15 PM |
| Abbott Laboratories' (ABT) Overweight Rating Reaffirmed at Barclays PLC
www.americanbankingnews.com - July 22 at 8:53 PM |
| Abbott Labs (ABT) PT Raised to $62 at Argus on 2Q Beat & FY17 Raise; 'Positive View of Growth Prospects' - StreetInsider.com
www.streetinsider.com - July 21 at 9:40 PM |
| Abbott Labs (ABT) PT Raised to $57 at Barclays on 2Q Beat & FY17 EPS Raise; '2H Outlook Appears Bright' - StreetInsider.com
www.streetinsider.com - July 21 at 9:40 PM |
| Abbott Laboratories' (ABT) "Buy" Rating Reaffirmed at Stifel Nicolaus
www.americanbankingnews.com - July 21 at 5:29 PM |
| Today's Research Reports on Stocks to Watch: Abbott Laboratories and Pfizer Inc.
finance.yahoo.com - July 21 at 4:38 PM |
| Company News for July 21, 2017
finance.yahoo.com - July 21 at 4:38 PM |
Abbott Laboratories (ABT) Chart for Sunday, August, 20, 2017
